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PI3K Modulates the Cardiac Response to
Chronic Pressure Overload by Distinct
Kinase-Dependent and -Independent Effects
indicate that PI3K is an essential component of a
complex controlling PDE3B phosphodiesterase-medi-
ated cAMP destruction. Thus, cardiac PI3K partici-
pates in two distinct signaling pathways: a kinase-
dependent activity that controls PKB/Akt as well as
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Hence, at least three class I PI3Ks can be found in heart
(Prasad et al., 2003). Cardiac-specific expression of aSummary
constitutively active PI3K increases heart size, and,
conversely, expression of a dominant-negative p110The G protein-coupled, receptor-activated phospho-
inositide 3-kinase  (PI3K) mediates inflammatory re- significantly reduces cardiac volume (Shioi et al., 2000).
In agreement with a role of PI3Ks in the modulation ofsponses and negatively controls cardiac contractility
by reducing cAMP concentration. Here, we report that cardiac size, the conditional inactivation in murine
hearts of PTEN, a phosphatase that counteracts PI3Kmice carrying a targeted mutation in the PI3K gene
causing loss of kinase activity (PI3KKD/KD) display re- activity, causes increased heart size and hypertrophic
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Figure 1. Targeting of a Kinase-Dead PI3K in the Murine PI3K Locus and Immunologic Phenotypes of Mice Expressing the Kinase-Dead
PI3K Mutant
(A) Strategy for the knockin replacement of PI3K by its kinase-dead (KD) mutant and generation of the KDNeo allele. Probe 1 was used to
detect the gene targeting event, and probe 2 was used to detect Cre-mediated deletion of the resistance cassette (dotted lines). E, EcoRI;
H, HinDIII; N, NotI; S, SacI; X, XbaI.
(B) Genotypic analysis of recombinant ES cell clones. Genomic DNA was digested with XbaI and analyzed by Southern blot with probe 1.
(C) Cre-mediated deletion of the neomycin resistance cassette. DNA from mouse tails was cut with EcoRI and probed with probe 2.
(D) Western blot analysis of PI3K, PI3K expression in PI3KKD/KD macrophages. Vinculin is detected for normalization.
(E) Western blot analysis of PKB/Akt phosphorylation on Ser473 in bone marrow-derived macrophages 5 min after stimulation with vehicle
(C), 1 M CCL5, or 10 nM C5a.
(F) Chemotactic response to vehicle (Ctrl), 5 nM C5a, 10 nM CCL5, or 16 nM PMA of thioglycollate-elicited peritoneal macrophages. Wild-
type littermates from heterozygous crosses were used as control for each mutant strain. Results are shown as the mean  SEM of five
triplicate experiments.
(G) Peritoneal recruitment of macrophages (MØ) or neutrophils (NØ) 12 hr after induction of septic peritonitis by intraperitoneal administration
of 107 CFU of E. coli (ATCC 25922). Results represent the mean  SEM of six mice of each genotype.
cient genetic background rescues the impaired cardiac tions but no alterations in cardiac contractility. We show
that cAMP levels are normal in PI3KKD/KD hearts andcontractility observed in PTEN mice but does not rescue
cardiac hypertrophy, thus suggesting different roles for that mice lacking PI3K (PI3K/ mice) but not
PI3KKD/KD mice develop dramatic myocardial damagecardiac class IA and IB PI3Ks (Crackower et al., 2002).
PI3K reduces cardiac contractility by inducing platelet- after TAC. Finally, we indicate that PI3K is involved in
cAMP metabolism independently of its kinase activity byactivating, factor-mediated nitric oxide production (Allo-
atti et al., 2003) but also by decreasing the basal level being an essential component of a complex controlling
PDE3B phosphodiesterase-mediated cAMP hydrolysis.of cAMP (Crackower et al., 2002).
Signaling through GPCRs and PI3K is considered to Together, these results unveil PI3K as a multifunctional
protein capable of relaying, in heart, both kinase activity-be involved in the pathogenesis of cardiac hypertrophy
and heart failure. Indeed, PI3K activity is increased dependent and -independent signaling events.
in hearts of mice subjected to pressure overload by
transverse aortic constriction (TAC) (Naga Prasad et al., Results
2000). PI3K also plays a role in the effects of chronic
-adrenergic (A) receptor stimulation detected in the Knockin Mice Expressing a Kinase-Dead PI3K
Show Impaired Chemoattractant-Drivenfailing heart. For example, PI3K/ mice are protected
from hypertrophy, fibrosis, and cardiac dysfunction Signaling and Leukocyte Recruitment
Others and we have recently indicated that PI3K/caused by long-term exposure to the A receptor ago-
nist isoproterenol (Oudit et al., 2003). Furthermore, mice are protected from the development of inflamma-
tory diseases. These findings incited considerable re-PI3K binds -ARK1 and participates in a complex that
favors clathrin-coated pits-mediated A receptor inter- search efforts with the aim of using PI3K kinase activity
as a target for the development of novel drugs (Wymannnalization (Naga Prasad et al., 2002). As other PI3Ks,
like PI3K, can bind -ARK1, PI3K/ mice do not show et al., 2003a). To better address this possibility, a
knockin mouse strain expressing a kinase-dead PI3Kany abnormality in A receptor densities (Nienaber et
al., 2003). However, overexpression in the mouse heart mutant (Stoyanova et al., 1997) under the control of the
endogenous locus was generated (Figures 1A–1C). Miceof a kinase-dead PI3K causes a specific defect in A
receptor internalization and protects from myocardial homozygous for the kinase-dead PI3K (PI3KKD) ex-
pressing allele (PI3KKD/KD mice) did not show any overtinjury induced by catecholamine excess and chronic
pressure overload (Nienaber et al., 2003). phenotype. Analysis by RT-PCR of PI3K expression
from PI3KKD/KD leukocytes revealed the exclusive pro-Here, we report that mice carrying a targeted mutation
in the PI3K gene causing loss of kinase activity duction of the PI3KKD mutant mRNA. Moreover, analysis
of protein expression in homozygous macrophages(PI3KKD/KD mice) display reduced inflammatory reac-
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revealed that the amount of PI3KKD expressed by cle; sham: 80.5  2.3, 7 days TAC: 135.7  1.7 m2 for
PI3K/ left ventricle; p 	 0.05, wild-type versus PI3KPI3KKD/KD cells matched that of PI3K/ controls (Fig-
ure 1D). Consistent with the crucial role of PI3K cata- null TAC).
Microscopic inspection of the necrotic areas oflytic activity in the GPCR-mediated induction of PKB/Akt
activation (Hirsch et al., 2000), PI3KKD/KD macrophages PI3K/ hearts indicated the presence of infiltrating
inflammatory cells mainly consisting of macrophagesfailed to activate PKB/Akt in response to the GPCR
agonists CCL5 and C5a (Figure 1E). As in PI3K/ con- (Figure 2F). This was unexpected, as it had been pre-
viously reported that the lack of PI3K caused reducedtrols, PI3KKD/KD macrophages showed a significantly re-
duced chemotactic response to these GPCR agonists macrophage migration in response to a wide range of
chemotactic stimuli (Hirsch et al., 2000). However, in-but not to PMA (Figure 1F). Furthermore, in a model of
E. coli-induced septic peritonitis, peritoneal recruitment flammatory cells (but not cardiomyocytes) stained posi-
tive for phosphorylated PKB/Akt, thus suggesting theof PI3KKD/KD neutrophils and macrophages was as dra-
matically reduced (Figure 1G) as in PI3K/ controls activation of a PI3K-independent recruitment mecha-
nism (Figure 2F).(Hirsch et al., 2000). Altogether, these data indicate that,
in leukocytes, the kinase activity of PI3K is necessary
for GPCR-mediated PKB/Akt activation and chemotac- Mice Expressing the Kinase-Dead PI3K Are
tic response. Protected from Cardiac Tissue Damage
Caused by Increased Workload
The impact of the PI3KKD mutant expression on cardiacPI3K-Deficient Mice Show Massive Cardiac
Necrosis after Transverse Aortic Constriction responses to TAC was next investigated. First, basal
cardiac functions were determined in 8-week-oldBesides its function in inflammatory cells, PI3K plays
a role in the negative control of cardiac contractility and PI3KKD/KD: echocardiographic and hemodynamic analy-
sis did not show any difference compared to wild-typein cardiac response to mechanical stress (Crackower et
al., 2002; Naga Prasad et al., 2000; Oudit et al., 2003). controls. In contrast to PI3K/ mice, measurement of
FS and dP/dT-max in PI3KKD/KD mice showed normalAccordingly, exposure of wild-type mice to chronic
pressure overload by TAC caused the progressive contractility. Next, we investigated whether hearts from
PI3KKD/KD mice developed, in response to chronic pres-upregulation of PI3K expression (Figure 2A).
Seven days after TAC, banded PI3K/ mice unex- sure overload, the same myocardial damage detected
in the PI3K/ genetic background. In response to TAC,pectedly exhibited signs of cardiac failure that were
not detectable in wild-type controls subjected to similar the PI3KKD mutant protein was upregulated similarly to
its wild-type counterpart (Figure 3A). Nevertheless, insystolic pressure gradients (60.6  5.4 versus 62.4 
5.8 mm Hg, mean  SEM, n 
 20 and 11, respectively; contrast to what was observed in PI3K/ mice, echo-
cardiographic analysis 7 days after TAC revealed thatn.s.). Echocardiography indeed revealed that cardiac
structure and function of PI3K/ mice were severely PI3KKD/KD mice maintained a preserved left ventricular
function (Figures 3B–3D, Table 1). Furthermore, in com-compromised (Figures 2B and 2C, Table 1). In contrast
to PI3K/ controls, PI3K/mice showed an impaired parison to wild-type controls subjected to similar gradi-
ents of pressure overload, PI3KKD/KD mice showed athickening of the left ventricular walls with evident cham-
ber enlargement revealed by 70% increase of LVEDD reduced left ventricular hypertrophic response, as evi-
denced by the decreased left ventricular wall thickening(Figures 2B and 2C). Measurement of percent fractional
shortening (FS) and dP/dT-max indicated that left ven- (Figure 3C, Table 1) and LV/BW (Figure 3D). In agree-
ment, measurement of left ventricular cardiomyocytetricular contractility in sham-operated PI3K/ mice
was significantly higher than in wild-type controls. How- areas indicated that PI3KKD/KD cardiomyocytes were
significantly smaller than wild-type and PI3K/ con-ever, 7 days after TAC, a marked deterioration of these
parameters was detected only in mutant mice where FS trols (sham: 79.5  2.3, 7 days TAC: 107.7  2.3 m2
for PI3KKD/KD left ventricles; p 	 0.05, PI3KKD/KD TACdropped by 46% and dP/dT-max by 60% (Figure 2C,
Table 1). Altogether, these data indicate that, in the versus wild-type and PI3K null TAC).
Anatomical and histological analysis of PI3KKD/KD leftabsence of PI3K, pressure-overloaded left ventricles
rapidly develop the typical signs of chamber dilatation ventricles subjected to 7 days of TAC with a pressure
gradient equal to or stronger than 40 mm Hg neverand dysfunction.
Anatomical inspection of hearts subjected to a pres- showed the presence of the necrotic lesions detected
in similarly treated PI3K-deficient mice. Furthermore,sure gradient higher than 40 mm Hg for 7 days revealed
a multifocal myocardial damage in PI3K/ samples extracellular matrix deposition was dramatically re-
duced in the PI3KKD/KD genetic background (Figures 3Ethat was absent in controls (Figure 2D). Histological
analysis of the lesions showed regions of massive car- and 3F). In addition, immunostaining of pressure-over-
loaded PI3KKD/KD hearts with anti-CD18 and anti-F4/diomyocyte loss and fibrotic substitution (Figure 2E).
Detection of extracellular matrix deposition evidenced 80 antibodies did not reveal any significant leukocyte
infiltration (Figure 3E). On the other hand, detection ofa dispersed pattern in wild-type cardiac samples but a
predominant distribution around the necrotic regions in activated PKB/Akt evidenced a marked reduction in im-
munoreactivity throughout the ventricle wall. As a whole,mutant hearts. In PI3K/ mice, the left ventricle mass
was not reduced in comparison to that of wild-type mice these results indicate that the expression of kinase-dead
PI3K results in a cardiac response to TAC different(data not shown), but the mean cardiomyocyte cross-
sectional area was smaller than controls (sham: 79.5  from that caused by either the absence of the protein
or the presence of its wild-type form.1.8, 7 days TAC: 183.9 2.5 m2 for PI3K/ left ventri-
Cell
378
Kinase-Dependent and Independent Function of PI3K
379
Table 1. Echocardiographic and Hemodynamic Parameters Before and After 7 Days of TAC in Mutant Mice and their Respective
Wild-Type Littermates
PI3K/ PI3K/ PI3K/(a) PI3KKD/KD
Basal TAC Basal TAC Basal TAC Basal TAC
n 
 5 n 
 6 n 
 5 n 
 6 n 
 5 n 
 5 n 
 5 n 
 5
BW (g) 22.3  1.0 21.2  0.6 23.2  0.6 20.0  1.3 22.6  1.5 21.4  1.5 22.9  0.6 22.6  0.3
HR (bpm) 636  25 600  37 629  21 570  12c 630  30 629  21 636  26 641  27
LVEDD (mm) 3.30  0.06 2.93  0.03c 3.17  0.13 4.07  0.07 3.44  0.04 2.95  0.10c 3.31  0.05 2.84  0.16c
LVESD (mm) 1.58  0.04 1.34  0.04c 1.28  0.09b 3.06  0.14b,c 1.63  0.07 1.31  0.02c 1.50  0.02 1.23  0.14
IVSTD (mm) 0.68  0.03 1.20  0.05c 0.69  0.01 0.68  0.03b 0.74  0.02 1.19  0.07c 0.67  0.03 1.03  0.04b,c
PWTD (mm) 0.63  0.01 1.17  0.03c 0.67  0.01b 0.72  0.06b 0.66  0.02 1.19  0.12c 0.64  0.03 1.00  0.05c
FS (%) 51.9  1.4 54.1  1.3 59.5  2.0b 24.9  3.2b,c 53.0  1.2 55.4  1.3 54.3  3.6 56.7  3.1
RWT 0.40  0.02 0.81  0.03c 0.43  0.02 0.34  0.02b,c 0.42  0.01 0.81  0.03c 0.40  0.01 0.72  0.07b,c
LVMI 2.93  0.09 6.17  0.28c 2.77  0.07 6.19  0.54c 3.21  0.05 6.19  0.54c 2.86  0.17 4.32  0.82b,c
Vcf (circ/s) 7.94  0.39 8.53  0.39 9.15  0.47b 3.95  0.54b,c 8.01  0.23 8.63  0.35 8.21  0.79 8.70  0.64
dP/dT-max 9236  431 12929  437c 12025  277b 4924  459b,c 9481  348 12743  340c 9557  351 12231  381c
dP/dT-min 8839  434 10284  412c 11507  225b 4262  340b,c 8678  333 10444  281c 8934  268 10003  403c
BW, body weight; HR, heart rate; bpm, beats per minute; LVEDD, left ventricle end diastolic diameter; LVESD, left ventricle end systolic
diameter; IVSTD, interventricular septum thickness in end diastole; PWTD, posterior wall thickness in end diastole; FS, percent fractional
shortening; RWT, relative wall thickness; LVMI, left ventricular mass index; Vcf, velocity of circumferential fiber shortening; dP/dT-max, maximal
rate of pressure development; dP/dT-min, maximal rate of pressure decay.
a Wild-type littermates of PI3KKD/KD mice.
b p 	 0.05 versus wild-type mice.
c p 	 0.05 versus basal conditions.
PI3K Kinase Activity Controls PKB/Akt and 4C). Consistent with a reduction in MAPK activation, the
expression of the MAPK-regulated Egr-1 transcriptionMAPK Activation in Pressure-Overloaded Hearts
The distinct effects raised by TAC in PI3K/ and factor was not upregulated in the two mutant strains,
thus demonstrating that the kinase activity of PI3K isPI3KKD/KD may be due to different signaling defects. To
investigate the impact of the absence or the enzymatic needed for activation of the PKB/Akt and the MAPK
pathways.inactivation of PI3K on cardiac intracellular signaling,
we first analyzed the phosphorylation state of proteins
reported to be triggered by TAC, such as PKB/Akt, PI3K Controls cAMP Homeostasis
Independently of its Kinase ActivityErk1/2, and p38. To focus on primary signaling events
and to avoid any interference caused by the critical It has been previously shown that PI3K modulates
baseline cAMP levels in isolated cardiomyocytestissue damage detected in PI3K/ hearts after 7 days
of pressure overload, we analyzed samples at 10 min (Crackower et al., 2002). To determine if an alteration in
cAMP levels in hearts may contribute to the differentand 5 hr after TAC.
In response to 10 min of pressure overload, hearts phenotype observed in response to TAC in PI3K/
and PI3KKD/KD mice, cardiac cAMP concentration wasfrom wild-type, PI3K/, and PI3KKD/KD showed an
equal increase in PKB/Akt, Erk1/2, and p38 phosphory- evaluated in all three genotypes. Interestingly, baseline
cAMP concentration in hearts of sham-operatedlation over the levels of sham-operated mice (data not
shown). Intriguingly, however, the analysis performed PI3K/ mice was significantly higher than that of wild-
type and PI3KKD/KD controls, which instead showed5 hr after TAC showed that, while in wild-type left ventri-
cles, phosphorylation of PKB/Akt, Erk1/2, and p38 re- identical cAMP levels (Figure 5A). Ten minutes of TAC
generated no significant variation in cAMP levels of allmained elevated over sham-operated controls, in
PI3K/ and PI3KKD/KD cardiac extracts, activation of three genotypes (Figure 5A). By contrast, 5 hr after TAC,
PI3K/, PI3K/, and PI3KKD/KD hearts showed a sig-the three kinases was significantly blunted (Figures 4A–
Figure 2. Effects of Cardiac Pressure Overload in PI3K-Deficient Hearts
(A) Analysis by immunoprecipitation of PI3K expression during 7 days of transverse aortic constriction (TAC). Vinculin is detected for normal-
ization.
(B) M-mode echocardiographic imaging of contracting hearts 7 days after TAC.
(C) Analysis of left ventricular end diastolic diameter (LVEDD, expressed in mm), diastolic interventricular septum thickness (IVSTD, expressed
in mm), and percent fractional shortening (FS) of 8-week-old mice 7 days after TAC. Mean  SEM was determined by echocardiography, n 

6 for each genotype. *p 	 0.01 between groups, determined by ANOVA.
(D) Representative hearts after 7 days of TAC. An example of necrotic lesions detected in mutant hearts subjected to pressure gradients
above 40 mm Hg is indicated by the arrow.
(E) Histological analysis of hearts before (Sham) and after 7 days of TAC (TAC). In the two leftmost panels, sections are stained with Picrosirius
red to visualize collagen fibril deposition in red. Nonspecific red labeling is detected in cellular debris found in the areas of necrosis. In the
rightmost panel, sections are stained with Masson’s Trichrome to visualize collagen fibrils in light blue. Scale bars, 100 m. Cell debris is not
stained as noticeably in the high-power magnification image shown in the inset. Scale bar, 200 m.
(F) Immunohistochemical analysis of inflammatory cells detected in hearts before (insets) or after 7 days of TAC. Scale bar, 100 m.
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Figure 3. Effects of TAC in PI3KKD/KD Hearts
(A) Analysis by immunoprecipitation of kinase-dead PI3K (PI3KKD) expression during 7 days of TAC. Vinculin is detected for normalization.
(B) M-mode echocardiographic imaging of contracting hearts before (Sham) and 7 days after TAC. Identical responses in mice of both
genotypes. (C) Analysis of left ventricular end diastolic diameter (LVEDD, expressed in mm), diastolic interventricular septum thickness (IVSTD,
expressed in mm), and percent fractional shortening (FS) of 8-week-old wild-type mice 7 days after TAC. Mean values  SEM were determined
by echocardiography, n 
 6 for each genotype. *p 	 0.05 PI3K/ versus PI3KKD/KD hearts. (D) Left ventricular weight, body weight ratio
(LVW/BW) plotted against the systolic pressure gradient as a difference between right and left carotid systolic blood pressure (P) at 7 days
after TAC. (E) Histological analysis of PI3KKD/KD hearts 7 days after TAC. (Upper panels) Sections before (Sham) and 7 days after TAC (TAC),
stained by Picrosirius red (two leftmost panels) and by Masson’s Trichrome (rightmost panel). (Lower panels) Immunohistochemical analysis
of inflammatory cells and of PI3K signaling before (inset) and after TAC. Scale bars, 100 m. (F) Morphometric quantitation of fibrosis in
Picrosirius red stained heart sections before (Sham) and after TAC. n 
 4 per group, with three sections from each heart.** p 	 0.01 PI3K/
versus PI3KKD/KD overloaded hearts. All p determined by ANOVA.
Kinase-Dependent and Independent Function of PI3K
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of cardiac PLN was stronger in PI3K/ sham-operated
mice than in wild-type and PI3KKD/KD controls (Figure
5B). Moreover, phosphorylation of phospholamban 5 hr
after TAC was low in PI3K/ and PI3KKD/KD cardiac
extracts but was significantly increased in hearts lacking
PI3K (Figure 5B). Altogether, these data show that
PI3K controls cardiac cAMP levels independently of
its kinase activity.
To determine whether, in PI3K/ hearts, the alter-
ation of cAMP level played a role in the development
of TAC-induced myocardial injury, mice were treated
intraperitoneally with the nonselective  blocker pro-
pranolol, a drug well-recognized to lower cAMP levels.
Measurement of cAMP at 5 hr after TAC in mice treated
with propranolol immediately after surgery showed that,
in hearts lacking PI3K, the drug significantly reduced
the cAMP increase following aortic banding (Figure 5C).
To analyze the long-term effects of propranolol on
PI3K/ hearts subjected to pressure overload, mice
were repeatedly treated with this drug over 7 days (15
mg/kg per day). Remarkably, this treatment blocked
the formation of the necrotic lesions in left ventricles
subjected to pressure gradients above 40 mm Hg. Ac-
cordingly, echocardiographic analysis revealed that, in
conditions of chronic pressure overload, propranolol
protected PI3K/ mice from a rapid progression to
heart failure and allowed the onset of a concentric hyper-
trophic remodeling (Figure 5D, Tables 1 and 2). Sham-
operated and banded PI3K/ mice treated with pro-
pranolol still showed a slightly increased myocardial
contractility compared to treated wild-type controls
(Figure 5D, Table 2), suggesting that cAMP concentra-
tion was reduced by propranolol below the critical
threshold for myocardial injury but that it was still high
enough to maintain a positive effect on cardiac contrac-
tility. Nevertheless, histological analysis 7 days after
TAC of propranolol-treated PI3K/ hearts showed a
reduction in the fibrotic reaction identical to that ob-
served in PI3KKD/KD cardiac samples (Figure 5E). Overall,
these data indicate that the aberrant elevation of cAMP
caused by lack of PI3K is responsible for the TAC-
induced heart failure in PI3K/ mice.
Cardiac PI3K Is Constitutively AssociatedFigure 4. TAC-Induced Effects on PKB/Akt, MAPK Activation, and
Egr-1 Induction in PI3K Mutant Hearts with PDE3B
To understand how the lack of PI3K affected cardiac(A) Western blot analysis of PKB/Akt phosphorylation on Ser473
and total PKB/Akt protein levels before (S) and 5 hr after TAC (given cAMP metabolism, we first analyzed whether PI3K
are three representative distinct mice). (B) Western blot analysis of could play a role in the Gi-mediated inhibition of adenyl-
Erk1 and 2 phosphorylation and total Erk1/2 protein levels in individ- ate cyclase. Total cardiac cAMP concentration was thus
ual hearts as above. (C) Western blot analysis of p38 phosphoryla-
measured in mice of all three genotypes after treatmenttion and total p38 protein levels in individual hearts as above. (D)
with the Gi blocker pertussis toxin. Five hours after TAC,Western blot analysis of Egr-1 expression in individual hearts as in
pertussis toxin-treated PI3K/ mice still showed a(A). Vinculin is detected for normalization. All data are representative
of ten individuals for each genotype giving identical results. strong elevation of cAMP levels (Figure 6A), thus sug-
gesting that, in PI3K/hearts, an aberrantly decreased
activity of Gi was not responsible for the elevated cAMP
levels. On the other hand, cAMP concentration dependsnificant increase in cAMP concentration over sham-
operated controls. However, the elevation of cAMP lev- on the balance between its production and its degrada-
tion by cyclic nucleotide phosphodiesterases. The con-els observed in PI3K/ hearts was dramatically higher
than that measured in PI3K/ and PI3KKD/KD hearts, centration of cAMP in hearts from mice of the three
genotypes was thus measured after treatment with thewhich showed equivalent values. In the heart, increased
cAMP causes activation of PKA, which phosphorylates nonselective phosphodiesterase inhibitor 3-isobutyl-1-
methylxanthine (IBMX). In this condition, cAMP in wild-phospholamban (PLN) in the sarcoplasmic reticulum.
Consistent with cAMP measurements, phosphorylation type and PI3KKD/KD samples reached a level similar to
Cell
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Figure 5. TAC-Induced cAMP Production and its Consequences in PI3K Mutant Hearts
(A) cAMP levels (mean  SEM) in total heart extracts before (Sham) and 10 min or 5 hr after TAC (n 
 9 for each genotype). *p 	 0.05, **p 	
0.01 PI3K/ versus PI3K/or PI3KKD/KD, #p	 0.05 TAC versus sham. (B) Western blot analysis of phospholamban (PLN) and its phosphoryla-
tion (P-PLN) before (S) and 5 hr after TAC. (C) cAMP levels (mean  SEM) in total heart extracts from PI3K/ and PI3K/ mice treated
intraperitoneally with 25 mg/kg of propranolol before (Sham; hatched bars) and 5 hr after TAC (crossed bars; n 
 5 for each genotype). §p 	
0.01 PI3K/ versus propranolol-treated PI3K/. (D) M-mode echocardiographic imaging of contracting hearts from sham operated or 7
days after TAC mice with daily propranolol administration. (E) Histological analysis of a PI3K/ heart 7 days after TAC and concomitant
treatment with 15 mg/kg per day of intraperitoneally administered propranolol. The section, representative of eight distinct individuals giving
similar results, is stained with Picrosirius red. Scale bar, 100 m. All p determined by ANOVA.
that of PI3K/ hearts (Figure 6B), strongly suggesting tion. We thus investigated whether a phosphodiesterase
(PDE) activity could associate to PI3K. Using an in vitroan impaired regulation of phosphodiesterase activity in
PI3K/ hearts. assay, PDE activity was measured in PI3K immunopre-
cipitates from PI3K/ total heart extracts. Strikingly,The normal cAMP levels in PI3KKD/KD hearts indicated
that cAMP concentration was not dependent on PI3K this method revealed that PI3K could coimmunopreci-
pitate with a PDE enzymatic activity that specificallykinase activity but possibly on protein/protein interac-
Table 2. Echocardiographic Parameters with Propranolol Treatment of Wild-Type and PI3K/ Mice Before and After 7 Days of TAC
PI3K/ PI3K/
Basal TAC Basal TAC
n 
 5 n 
 5 n 
 5 n 
 5
BW (g) 21.7  2.0 21.5  0.5 21.6  0.1 20.7  0.8
HR (bpm) 525  25c 546  19c 563  27c 540  20c
LVEDD (mm) 3.22  0.14 2.91  0.05 3.16  0.03 2.50  0.07a,b,c
LVESD (mm) 1.64  0.05 1.32  0.03 1.50  0.02a 0.94  0.01a,b,c
IVSTD (mm) 0.63  0.05 1.05  0.05b 0.71  0.02 1.01  0.04b,c
PWTD (mm) 0.63  0.06 1.00  0.05b,c 0.67  0.04 0.96  0.04b,c
FS (%) 49.1  1.3 54.6  0.9b 52.7  1.1a,c 62.4  0.4a,b,c
RWT 0.39  0.03 0.70  0.01b 0.44  0.01 0.79  0.05b,c
LVMI 2.76  0.43 4.76  0.28b,c 3.06  0.20 3.74  0.07a,b,c
Vcf (circ/s) 6.97  0.19c 7.52  0.34c 6.94  0.15c 10.09  0.10a,b,c
BW, body weight; HR, heart rate; bpm, beats per minute; LVEDD, left ventricle and diastolic dimension; LVESD, left ventricle end systolic
dimension; IVSTD, interventricular septum thickness in end diastole; PWTD, posterior wall thickness in end diastole; FS, percent fractional
shortening; RWT, relative wall thickness; LVMI, left ventricular mass index; Vcf, velocity of circumferential fiber shortening.
a p 	 0.05 versus wild-type mice.
b p 	 0.05 versus basal conditions.
c p 	 0.05 versus no propranolol.
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Figure 6. Cardiac PI3K Is Associated with PDE3B
(A) cAMP levels (mean  SEM) in total heart extracts from mice treated intraperitoneally with pertussis toxin (PTX; 100 mg/kg) before (Sham)
and 5 hr after TAC (TAC, n 
 6 for each genotype). *p 	 0.01 between groups. (B) cAMP levels (mean  SEM) in total heart extracts from
mice treated intraperitoneally with 20 mg/kg of the nonselective phosphodiesterase inhibitor IBMX before (Sham) and 5 hr after TAC (TAC,
n
 4 for each genotype). (C) Measurement of cardiac cAMP phosphodiesterase (PDE) activity coimmunoprecipitated with anti-PI3K antibodies.
Incubation time with labeled cAMP is indicated in minutes. (D) Inhibition with 10 M IBMX of the cAMP PDE activity coimmunoprecipitated
with anti PI3K antibodies. (E) Pharmacological characterization of the PDE isoform coimmunoprcipitated with PI3K. Erythro-9-(2-Hydroxy-
3-nonyl)adenine hydrochloride (ENHA, 10 M), enoximone (ENOX, 10 M), Ro 201724 (RO, 10 M), rolipram (ROL, 10 M), and zaprinast
(ZAPR, 10 M) inhibit PDE2, PDE3, PDE4, PDE4, and PDE5/6, respectively. The dashed line represents the maximal PDE activity detected in
control PI3K immunoprecipitates from PI3K/ heart extracts. *p 	 0.001 between groups. (F) Western blot analysis of PDE3A expression
in hearts (left panel). Western blot analysis does not reveal the presence of PDE3A in the PI3K immunoprecipitate (right panel). (G) Western
blot analysis of PDE3B expression in hearts (left panel). Western blot detection of PDE3B in PI3K immunoprecipitates (right panel). (H)
Western blot analysis of PDE3B immunoprecipitated from hearts. PDE3B can be immunoprecipitated from tissues of all three genotypes
without contamination of PDE3A (left and central panel, respectively). PI3K coimmunoprecipitates with PDE3B (right panel). (I) Analysis of
PDE3B enzymatic activity in hearts. In PDE3B immunoprecipitates from PI3K/ hearts, PDE3B catalytic activity is reduced (p 	 0.001
PI3K/ versus PI3K/ or PI3KKD/KD; n.s., PI3K/ versus PI3KKD/KD; n 
 5 for each set of experiments). Addition of recombinant PI3K
(rPI3K) to the PI3K/ cardiac extracts rescues PDE3B activity (Pre IP; hatched bar; *p 	 0.01 PI3K/ versus PI3K/  rPI3K; n 
 4).
Conversely, addition of rPI3K to the immunoprecipitated PDE3B from PI3K/ extracts does not significantly increase the PDE activity (Post
IP; crossed bar; n 
 4). All p determined by ANOVA.
degrades cAMP (Figure 6C). To exclude the possibility itated from PI3KKD/KD hearts (2.8  0.05 cpm  104 at
120 min, PI3KKD/KD versus PI3K/ n.s.; n 
 3). On thethat a PDE was unspecifically recognized by the anti-
PI3Kantibody, the assay was repeated using the immu- other hand, the addition of the PDE inhibitor IBMX to
PI3K immunoprecipitates decreased the PDE activitynoprecipitate of extracts derived from PI3K/ hearts.
In this case, no relevant PDE activity was observed (Fig- to background levels (Figure 6D), thus indicating that,
in cardiac tissue, PI3K indeed associates with a PDE.ure 6C). PI3K association with the PDE activity ap-
peared constitutive and not susceptible to A modula- To determine which type of PDE activity was involved
in this association, different class-specific PDE inhibi-tion: identical enzymatic activities could be retrieved
from hearts in basal conditions as well as from hearts tors were tested (Figure 6E), and only enoximone, a class
3 PDE inhibitor, significantly reduced the PDE activitytreated with isoproterenol prior to homogenization. To
test whether PI3K itself could degrade cAMP, the PDE observed in immunoprecipitates, thus indicating that
cardiac PI3K is associated with PDE3 (Figure 6E).enzymatic assay was performed with recombinant hu-
man PI3K, but no activity could be detected (data not To date, two different PDE3 isoforms, PDE3A and
PDE3B, have been described (Movsesian, 2002). West-shown). Consistently, a PDE activity was immunoprecip-
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ern blot analysis revealed that these two isoforms were after aortic banding, the kinase activity of PI3K is re-
quired for the sustained phosphorylation of PKB/Akt asequally expressed in hearts of all three genotypes (Fig-
well as Erk1/2 and p38. This is probably due to theures 6F and 6G). To investigate the nature of the PDE3
release, at this time point, of neurohumoral factors suchsubtype associated with PI3K, immunoblots with iso-
as catecholamines (Brede et al., 2002; Rapacciuolo etform-specific anti-PDE3 antibodies were performed on
al., 2001) that may activate PI3K. Indeed, the reductionPI3K immunoprecipitates. While no PDE3A was de-
of PKB/Akt phosphorylation in the two mutant geno-tected in PI3K immunoprecipitates obtained from all
types is consistent with the strict dependence of thisthree genotypes (Figure 6F), PDE3B readily coimmuno-
process on PtdIns(3,4,5)P3 production. In the heart,precipitated with PI3K from both wild-type and PI3KKD
PKB/Akt activation protects from apoptosis but alsoheart extracts (Figure 6E).
influences cell size. For example, reduction of PKB/AktTo test whether the association with PI3K controls
activation by a kinase-dead PI3K reduces cardiac sizethe catalytic activity of PDE3B, this phosphodiesterase
(Shioi et al., 2000). Furthermore, transgenic mice ex-was immunoprecipitated from hearts of the three geno-
pressing a constitutively active PKB/Akt in the hearttypes, and PDE activity in the pellet was analyzed. As
spontaneously develop cardiac hypertrophy and dilata-shown in Figure 6H, PDE3B could be specifically immu-
tion (Matsui et al., 2002). The reduction of left ventricularnoprecipitated from hearts of all three genotypes with-
hypertrophy detected in PI3K/ and PI3KKD/KD heartsout any PDE3A contamination. In agreement with the
7 days after TAC can thus be explained by a decreasedresults of Figure 6G, the presence of PI3K could be
activation of PKB/Akt.evidenced in the PDE3B immunoprecipitates from
The phosphorylation of Erk1/2 and p38 as well as thePI3K/ and PI3KKD/KD but not from PI3K/ cardiac
upregulation of the transcription factor Egr-1 are knownextracts (Figure 6H). Measurement of PDE activity in the
to play a crucial role in the pathogenesis of cardiacpellets revealed that PDE3B was significantly less active
remodeling and fibrosis (Bueno and Molkentin, 2002;in PI3K/ than in PI3K/ and PI3KKD/KD samples
Manabe et al., 2002). Transgenic mice selectively over-(70% decrease compared to the activity in PI3K/
expressing an activated form of p38 in the heart showsamples, Figure 6I), thus indicating that the presence of
constitutive fibrotic degeneration of the left ventriclePI3K controls PDE3B activity. To further confirm this
(Liao et al., 2001; Zhang et al., 2000). Similarly, micehypothesis, we investigated whether recombinant PI3K
heterozygous for a null allele of Grb2, an adaptor proteincould rescue PDE3B activity in PI3K/ samples. As
involved in p38 activation, appear protected from theshown in Figure 6I, addition of recombinant PI3K to
TAC-induced cardiac fibrosis (Zhang et al., 2003).heart extracts before immunoprecipitation significantly
Hence, the reduction of the PI3K kinase-dependentrescued the PDE3B activity retrieved from PI3K/
activation of MAPKs may be the main reason for thesamples (Figure 6I). This effect appeared kinase inde-
protection from fibrosis detected in PI3KKD/KD and pro-pendent, as it was not sensitive to the PI3K inhibitor
pranolol-treated PI3K/ hearts.LY294002 (10 M). Unexpectedly, however, addition of
The finding that the kinase activity of PI3K was re-recombinant PI3K to the PDE3B immunoprecipitates
quired for TAC-triggered signaling events did not explaindid not show a significant rescue of PDE activity (Figure
the different phenotypic responses to pressure overload6I), thus indicating that a direct interaction between the
detected in PI3K/ and PI3KKD/KD hearts. Protectiontwo proteins is not sufficient to drive PDE3B activation
from the development of necrotic lesions and fibrosisand that other molecular partners are needed. Overall,
observed in PI3KKD/KD hearts strongly suggests thatthese data demonstrate that PI3K is a crucial element
PI3K is involved in signaling processes unrelated to itsof a multimolecular complex controlling PDE3B function
kinase activity. A possible explanation for this differencein the intact heart.
could reside in the distinct amounts of cAMP found in
hearts of the two genotypes. In the heart, cAMP produc-
Discussion tion is triggered by Gs-coupled receptors, such as the
1-adrenergic receptor, which cause the activation of
To model the effects of catalytic activity inhibition of adenylate cyclase. Abnormal activation of the signaling
PI3K, we generated a mouse expressing a kinase-dead cascade involving cAMP elevation in heart is known to
PI3K and found that the phenotype of PI3KKD/KD mice cause necrotic cardiac tissue damage and fibrosis. For
only partially reproduced that of the knockout animals. example, transgenic mice overexpressing 1-adrenergic
Whereas both PI3K/ and PI3KKD/KD mice exhibited receptors in the heart spontaneously develop cardiomy-
an identical impairment in innate immune reactions, only ocyte loss and increased extracellular matrix deposition
PI3K/ mice showed a basal enhancement of cardiac (Engelhardt et al., 1999). Similarly, cardiac overexpres-
contractility. In order to evaluate this difference in more sion of Gs causes cardiomyocyte death and fibrosis
detail, we investigated the responses of hearts of these (Iwase et al., 1996). Moreover, similar effects can also
two genotypes to mechanical stress induced by aortic be induced by targeted cardiac production of a constitu-
constriction. We show that, in response to TAC, only tively active mutant of PKA, one of the major effectors
PI3K/ mice developed cardiac damage. In addition, of cAMP-mediated signaling (Antos et al., 2001). On the
we indicate that cAMP levels were normal in PI3KKD/KD other hand, A receptor antagonists like propranolol
hearts and that cardiac PI3K is a crucial component can limit the adverse effects of the A overdrive, thus
of a complex controlling PDE3B-mediated cAMP hydro- providing a basis for pharmacologic treatment of car-
lysis. diac failure. A paradigm for this concept is the report
Our results indicate that PI3K does not play a crucial that propranolol administration in mice overexpressing
Gs in the heart protects from the development of cardiacrole in the immediate response to TAC. However, 5 hr
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damage and fibrosis (Asai et al., 1999). Consistent with al., 2000). Our results extend the view that PI3Ks influ-
this view, treatment of PI3K/ mice after TAC with ence PDE3B function and indicate that cardiac PDE3B
propranolol decreased cAMP levels, protected from activity might be critically controlled by the formation
cardiomyocyte loss or fibrosis, and preserved cardiac of a complex with PI3K serving as a fundamental com-
function. ponent. Further studies are now needed to define the
All transgenic mouse strains with an increased A nature of the proteins involved in this process.
drive show slowly progressive myocardial degeneration Taken together, our data indicate that, in the pressure-
and fibrosis. However, none develop lesions with the overloaded left ventricle, PI3K plays a dual role: first,
rapidity (they usually appear after weeks) and the extent through its kinase activity, it controls MAPK and Akt
(they are normally evident only by histological examina- activation, which possibly induce fibrosis and hypertro-
tion) detected in aortic-banded PI3K/ mice. This ob- phy, respectively; second, via association with PDE3B, it
servation suggests that when an enhanced cAMP pro- induces cAMP level reduction and eventually negatively
duction is coupled to a strong left ventricular mechanical modulates cardiac contractility.
overload, the myocardial degeneration is accelerated
and intensified. In possible agreement with such a Experimental Procedures
model, chronic A stimulation by prolonged administra-
Gene Targeting of PI3Ktion of isoproterenol without a concomitant biomechani-
Mice lacking PI3K were generated as previously described (Hirschcal stress does not induce cardiac hypertrophy and fi-
et al., 2000). To generate knockin animals carrying a kinase-deathbrosis in PI3K/ mice (Oudit et al., 2003). These data
form of PI3K, wild-type PI3K locus was replaced by a chimeric
thus provide a further support to our finding that, after minigene containing a mutated form of the human cDNA, in which
TAC, the PI3K kinase activity is needed for the cardiac the Lys833 was converted into Arg, followed by a neomycin resis-
fibrotic response and suggest that elevation of A drive, tance gene (Neor) cassette sandwiched between loxP sequences.
Two out of four recombinant clones were used to generate germper se, is not sufficient to trigger cardiac wall degenera-
line-transmitting chimeras. Heterozygous mice were crossed withtion in a PI3K-deficient genetic background. With TAC
Balancer Cre mice to delete the Neor cassette. The responses ofbeing able to trigger catecholamine release in the heart
homozygous mutant leukocytes were studied as previously de-
(Brede et al., 2002; Rapacciuolo et al., 2001), we thus scribed (Hirsch et al., 2000).
hypothesize that only a combination of A hyperstimula-
tion together with mechanical stress can trigger the In Vivo Biomechanical Stress
massive cardiac tissue damage detected in PI3K/ Mechanical stress was imposed on the left ventricle by TAC, as
mice. Indeed, reduction of cAMP by propranolol rescues described (Brancaccio et al., 2003). 2D guided M-mode echocardi-
ography was performed in conscious mice with a GE System 5this TAC-induced effect and unmasks the conse-
echocardiograph. Cardiac catheterization was performed using aquences of the lack of PI3K enzymatic activity in
high-fidelity micromanometer catheter (Millar Instruments) (Bran-PI3K/ hearts.
caccio et al., 2003). The systolic pressure gradient and the degreeOur data strongly suggest that the effect of PI3K on
of biomechanical stress imposed on the left ventricle were measured
cardiac cAMP levels can be genetically uncoupled from repeating this procedure with left and right carotid arteries.
its kinase activity. This is in apparent contrast with previ-
ous reports indicating that PtdIns(3,4,5)P3 plays a role Analysis of Signaling Pathways
in A signaling and cAMP concentration balance like in At the indicated time after TAC, ventricles were rapidly removed,
mice lacking PTEN in the heart. Nevertheless, a large frozen, pestled in liquid nitrogen, and then boiled in a solution con-
taining 120 mM NaCl, 50 mM Tris-HCl (pH 8), 1% Triton X-100, 10body of evidence indicates that PI3Ks are essential for
g/ml leupeptin, 4 g/ml pepstatin, 0.1 TIU/ml aprotinin, 50 mMA receptor downregulation by internalization (Prasad
sodium fluoride, 1 mM sodium orthovanadate, and 10 mM sodiumet al., 2003). Thus, the putative effects of PtdIns(3,4,5)P3 pyrophosphate. After a brief sonication, solubilized proteins were
on cardiac contractility may be due to its influence on centrifuged at 14,000 rpm (4C) for 30 min, and supernatants were
A receptor densities. Alternatively, the decreased left stored at 80C.
ventricular contractility observed in mice lacking PTEN
could be a consequence of the overall cardiac enlarge- Histological Analysis and Immunohistochemistry
ment or the lack of its protein phosphatase activity. Paraffin-embedded left ventricles were cut into 5m slices. Sections
Hearts simultaneously lacking PTEN and PI3K res- were stained with Picrosirius red (Fluka, Buchs, Switzerland) and
Masson’s Trichrome (Bio-Optica, Milan, Italy). Fibrosis and the myo-cue the cardiac contractile deficiency of PTEN single
cyte cross-sectional area were measured using the Imageproplusmutants and display an enhanced cardiac contractility
software. Suitable cross-sections were defined as those showingsimilar to that observed when solely PI3K is lacking.
nearly circular capillary profiles and nuclei.
Our data strongly argue against an involvement of PI3K
kinase activity in this effect but rather imply that the
Antibodies
rescue is caused by the crucial role of PI3K in a protein Monoclonal and rabbit polyclonal antibodies against PI3K were
complex causing the reduction of cardiac cAMP levels. used as previously published (Alloatti et al., 2003; Hirsch et al.,
Indeed, our findings reveal that, in the heart, PI3K con- 2000). Rabbit polyclonal antibodies against phospho-Ser473-Akt,
stitutively associates with the phosphodiesterase PDE3B. total Akt, phospho-p38, and phospho-Erk1/2 were from New Eng-
land BioLabs (Beverly, Massachusetts, USA). Antibodies againstThis cGMP-inhibited phosphodiesterase isoform (Beavo,
Erk1 (C16) were from Santa Cruz Biotechnology (Santa Cruz, Califor-1995) has been previously found to be involved in PI3K
nia, USA), and those against p38 were from Immunological Sciencesignaling in multiple scenarios (Movsesian, 2002). In adi-
(Rome, Italy). Rabbit polyclonal antibody against phospho-Phos-
pocytes, PDE3B is activated by an insulin/PI3K-depen- pholamban (Ser16) and monoclonal antibody against Phospholam-
dent pathway either via PKB/Akt-mediated phosphory- ban were from Upstate Biotechnology (Lake Placid, New York, USA).
lation (Kitamura et al., 1999) or by directly acting as a Rat monoclonal antibodies against mouse CD18 and F4/80 were
from BMA (Augst, Switzerland).substrate for PI3K protein kinase activity (Rondinone et
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Determination of cAMP Content in Mouse Hearts Bondeva, T., Pirola, L., Bulgarelli-Leva, G., Rubio, I., Wetzker, R.,
and Wymann, M.P. (1998). Bifurcation of lipid and protein kinaseHearts were collected, powdered in liquid nitrogen, and extracted
with 6% trichloroacetic acid. Samples were sonicated for 10–15 s signals of PI3Kgamma to the protein kinases PKB and MAPK. Sci-
ence 282, 293–296.and centrifuged at 13,000 rpm for 15 min at 4C. Supernatants were
washed five times with six volumes of diethilether, desiccated in Brancaccio, M., Fratta, L., Notte, A., Hirsch, E., Poulet, R., Guazzone,
SpeedVac, and resuspended in TE buffer prior to cAMP measure- S., De Acetis, M., Vecchione, C., Marino, G., Altruda, F., et al. (2003).
ment by radiolabeled competitive protein binding assay (Cyclic AMP Melusin, a muscle-specific integrin beta1-interacting protein, is re-
[3H] Biotrak Assay System, Amersham Biosciences, Piscataway, quired to prevent cardiac failure in response to chronic pressure
New Jersey, USA). overload. Nat. Med. 9, 68–75.
Brede, M., Wiesmann, F., Jahns, R., Hadamek, K., Arnolt, C., Neu-
Immunoprecipitation bauer, S., Lohse, M.J., and Hein, L. (2002). Feedback inhibition of
Hearts were collected and immediately homogenized in 100 mM catecholamine release by two different alpha2-adrenoceptor sub-
NaCl, 50 mM Tris-HCl (pH 8.0), 0.3% Triton X-100, and protease types prevents progression of heart failure. Circulation 106, 2491–
inhibitors. Samples were sonicated for 20 s and centrifuged for 20 2496.
min at 4C at 20,000  g. Precleared extracts (3 mg of protein per
Bueno, O.F., and Molkentin, J.D. (2002). Involvement of extracellularsample) were then incubated with polyclonal antibodies overnight
signal-regulated kinases 1/2 in cardiac hypertrophy and cell death.at 4C.
Circ. Res. 91, 776–781.
Cantley, L.C. (2002). The phosphoinositide 3-kinase pathway. Sci-PDE Assay
ence 296, 1655–1657.PDE activity in immunoprecipitates was measured as described
(Thompson and Appleman, 1971). Briefly, washed immunoprecipi- Crackower, M.A., Oudit, G.Y., Kozieradzki, I., Sarao, R., Sun, H.,
tates were assayed in a total volume of 200 l of reaction mixture Sasaki, T., Hirsch, E., Suzuki, A., Shioi, T., Irie-Sasaki, J., et al. (2002).
containing 40 mM Tris-Cl (pH 8.0), 5 mM MgCl2, 10 mM 2-mercapto- Regulation of myocardial contractility and cell size by distinct PI3K-
ethanol, 1 M cAMP, and [3H]cAMP (0.1 Ci/tube, approximately PTEN signaling pathways. Cell 110, 737–749.
1 106 cpm/tube). Samples were incubated under agitation at 37C, Engelhardt, S., Hein, L., Wiesmann, F., and Lohse, M.J. (1999). Pro-
boiled for 1 min to stop reaction, and processed for scintillation gressive hypertrophy and heart failure in beta1-adrenergic receptor
counting of adenosine. PDE inhibitors were dissolved in DMSO or transgenic mice. Proc. Natl. Acad. Sci. USA 96, 7059–7064.
100% ethanol and diluted into reaction mixtures.
Hirsch, E., Katanaev, V.L., Garlanda, C., Azzolino, O., Pirola, L.,For rescue experiments, extracts derived from PI3K/ hearts
Silengo, L., Sozzani, S., Mantovani, A., Altruda, F., and Wymann,were incubated 1 hr at 25C in the presence of 500 ng/ml of recombi-
M.P. (2000). Central role for G protein-coupled phosphoinositidenant PI3K prior to the preclearing. Activity in the pellet was assayed
3-kinase gamma in inflammation. Science 287, 1049–1053.in the presence of 0.1M cAMP. Similarly, the activity of immunopre-
Iwase, M., Bishop, S.P., Uechi, M., Vatner, D.E., Shannon, R.P.,cipitated PDE3B was tested in the presence of 500 ng/ml of recombi-
Kudej, R.K., Wight, D.C., Wagner, T.E., Ishikawa, Y., Homcy, C.J.,nant PI3K.
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